Stock Watch: Beware The Halo Effect Of Biopharma Leaders
Serial Entrepreneurs Who Failed To Deliver Down The Line
Some entrepreneurs combine talent and experience to produce multiple profitable exits for investors. But there are many who do not, and past success is indeed no guarantee of future performance.
You may also be interested in...
As stock markets continue their retreat after the bull market which started in 2002, investors in biotechnology stocks have more than one reason to assume to a ‘risk-off’ stance.
Loss of exclusivity and other competitive pressures will continue to offset J&J’s pharmaceutical growth as its former blockbusters accumulate in ex-growth "other" categories. Can the pipeline take up the slack?
While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.